Business context and reporting period
The supplied filing is Novus Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2018—not a filing under the name Eledon Pharmaceuticals, Inc. Novus was an early-stage specialty pharmaceutical company developing treatments for ear, nose and throat disorders. Its lead candidate, OP-02, targeted otitis media; OP-01 development was paused while resources were focused on OP-02.
Financial performance and position
Amounts below are in U.S. dollars; financial-statement figures are in millions unless otherwise noted. Novus reported no product revenue and continued to incur operating losses.
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Research and development expense | $1.651 | $0.517 | $4.077 | $1.529 |
| General and administrative expense | $1.848 | $2.448 | $5.406 | $9.487 |
| Total operating expense | $3.499 | $2.965 | $9.483 | $11.016 |
| Net loss | $3.496 | $2.970 | $9.491 | $11.006 |
| Loss per share, basic and diluted | $0.37 | $0.43 | $1.07 | $2.25 |
At September 30, 2018, cash was $16.324 million, working capital was $15.5 million, total assets were $19.928 million, total liabilities were $1.603 million, and accumulated deficit was $36.997 million. The filing reports no interest-bearing debt. No gross margin or profit margin is meaningful given the absence of product revenue.
For the first nine months of 2018, operating cash use was $8.540 million, financing provided $7.561 million, and investing cash flow was zero; cash and restricted cash declined by $0.979 million to $16.324 million. In the comparable 2017 period, operating cash use was $12.330 million and investing cash flow included $23.250 million received in the merger.
Material changes versus prior comparable periods
- Q3 net loss increased $0.526 million year over year as operating expenses rose 18%. R&D expense increased $1.134 million, principally from OP-02 formulation development and clinical costs; G&A fell $0.600 million, largely because of lower merger-related costs.
- Nine-month net loss improved $1.515 million, with total operating expenses down 14%. R&D rose $2.548 million, primarily from OP-02 development; G&A fell $4.081 million, mainly reflecting $5.0 million of merger-related expenses in 2017, partly offset by higher public-company, legal and stock-based compensation costs.
- Common shares outstanding increased to 9.422 million from 7.110 million at year-end 2017. The company received approximately $7.5 million net from equity sales during the nine-month period. It filed a further $9.8 million equity offering prospectus in July 2018; no shares had been sold under it by the filing date.
Outlook, risks and unusual items
Management expected continuing losses and higher R&D spending as OP-02 development advanced. The company stated it believed cash would fund operations for at least 12 months from issuance of the statements, while also saying it contemplated raising capital during Q4 2018 and Q1 2019. If it could not obtain sufficient financing, it planned cost reductions beginning in Q1 2019, potentially including personnel reductions and delays or curtailment of R&D. Management stated it had concluded substantial doubt about going concern did not exist.
The filing described a planned OP-02 Phase 1 program, but also stated in its risk disclosures that the first OP-02 clinical studies had not yet begun. Timing and actual trial commencement therefore warrant confirmation. OP-02 had not been evaluated in human studies, and the company cited clinical, regulatory, manufacturing scale-up, financing, and third-party supply risks. OP-01 remained paused pending funding. The company referred to seeking strategic alternatives, but the supplied filing text gives no clear details or outcome.
Tokai-related securities lawsuits remained pending. The company intended to defend them and said it could not estimate a reasonably possible loss; no liability was accrued for contingencies at September 30, 2018. The company also disclosed potential future royalty repayment obligations on Israeli Innovation Authority grants, contingent on successful development and product sales; no liability was recorded because it had not generated sales.
Important facts for investors to verify
- Confirm the issuer identity: the filing names Novus Therapeutics, Inc., not Eledon Pharmaceuticals, Inc.
- Check whether OP-02 Phase 1 studies commenced, and compare actual development progress with the stated plans.
- Assess cash runway and financing: the runway statement, planned financing window, and possible Q1 2019 cost cuts are material.
- Verify subsequent use of the $9.8 million equity offering capacity and the resulting share dilution.
- Review updates to the Tokai securities litigation, strategic-alternatives process, and any related costs or contingencies.